The debate on whether NSAIDs have a chemopreventive role to play has resurfaced this week, with the latest analysis finding users of aspirin and other non-steroidal anti-inflammatory drugs have a significantly reduced risk for oesophageal cancers.
Compared to non-users, users of any NSAID had a 32% reduced risk of oesophageal adenocarcinoma (EAC) (CI, 0.56–0.82) and a 16% reduced risk of oesophagogastric junctional adenocarcinoma (EGJA) CI, 0.68–1.03), the pooled analysis of six population-based studies with over 2,300 oesophageal cancer patients found.
Writing in Gastroenterology, the US authors said this effect seemed to be restricted to current NSAID users.
Increasing frequency of use correlated with decreasing risk of EAC, as did NSAID use for any duration, but there was little evidence of a relationship between...
This site is intended for Registered Medical Practitioners.
To make the most of Oncology Update, you need to be logged in.